Surrozen, Inc. (SRZN)
NASDAQ: SRZN · IEX Real-Time Price · USD
9.00
-0.25 (-2.70%)
At close: Jul 19, 2024, 12:00 AM
8.92
-0.08 (-0.89%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Surrozen Employees
Surrozen had 42 employees as of December 31, 2023. The number of employees decreased by 32 or -43.24% compared to the previous year.
Employees
42
Change (1Y)
-32
Growth (1Y)
-43.24%
Revenue / Employee
n/a
Profits / Employee
-$894,643
Market Cap
28.79M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 42 | -32 | -43.24% |
Dec 31, 2022 | 74 | -9 | -10.84% |
Dec 31, 2021 | 83 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Rapid Micro Biosystems | 193 |
Bolt Biotherapeutics | 100 |
Enlivex Therapeutics | 71 |
Palatin Technologies | 34 |
Daré Bioscience | 26 |
bioAffinity Technologies | 14 |
Akari Therapeutics, | 12 |
RenovoRx | 8 |
SRZN News
- 5 weeks ago - Surrozen Publishes Study in ‘eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling - GlobeNewsWire
- 6 weeks ago - Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan - GlobeNewsWire
- 6 weeks ago - Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis - GlobeNewsWire
- 2 months ago - Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting - GlobeNewsWire
- 2 months ago - Surrozen Provides First Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 3 months ago - Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis - GlobeNewsWire
- 4 months ago - Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043 - GlobeNewsWire
- 4 months ago - Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire